High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis

Table 2 Organ involvement at onset (%)

	EGPA patients treated with IVIG within the period of initial treatment (n = 10)	EGPA patients treated with IVIG on relapse after remission (n = 7)	P
Asthma	100	100	NS^*
Paranasal sinusitis	90	85.7	NS^*
Multiple polyneuropathy	100	100	NS^*
Minimum MMT score, mean ± 1 SD	3.1 ± 0.9	4.1 ± 0.7	0.05^†
Pulmonary infiltrates	80	85.7	NS^*
Myocardial involvement	50	100	0.05^*
Gastrointestinal tract	80	100	NS^*
Liver, gall bladder, pancreas	16.7	30	NS^*
Renal involvement^‡	20	28.5	NS^*
Proteinuria	50	42.8	NS^*
Eosinophils in urine	28.6	40	NS^*
Nephritis or nephrosis	10	14.3	NS^*
Skin involvement	90	100	NS^*
Arthritis	40	42.8	NS^*
Myalgia	40	28.5	NS^*
Central nervous system involvement	30	28.5	NS^*
Number of organs involved per patient^‡‡, mean ± 1 SD	5.7 ± 1.1	6.3 ± 2.1	NS^†
FFS2009	1.5 ± 1.0	1.4 ± 1.0	NS^†

EGPA, eosinophilic granulomatosis with polyangiitis; FFS, five-factor score; IVIG, intravenous immunoglobulin; MMT, manual muscle test; NS, not significant.
All values are expressed as means ± 1 SD.
Values of P ≤ 0.05 were considered statistically significant.
^†Two-way ANOVA with repeated measures between groups.
*Chi-squared testing revealed no significant differences between groups.
^‡Renal involvement including proteinuria or eosinophils in urine or glomerular nephritis or nephrosis or renal dysfunction.
^‡‡Cumulative organ involvement excluding asthma and sinusitis.

ISSN: 2045-7022